Company
Headquarters: Beijing, China
Employees: 11,029
CN¥19.26 Billion
CNY as of Jan. 1, 2026
US$2.75 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its subsidiaries, operates as a pharmaceutical company in the People's Republic of China. The company offers soft bag, plastic and glass bottle, inner sealed polypropylene, and polypropylene blend bag infusion products; levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, sodium chloride injection products, etc.; and peritoneal dialysate, hemodialysis dialysate, etc. It also provides compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, edaravone, and other products to treat cardiovascular and cerebrovascular diseases. In addition, the company offers products for endocrinology; and pediatric compound amino acid injection, and other drugs to treat pediatrics. Further, it provides nutritional drugs, including vitamin E and C; and anti-infective drugs. The company is headquartered in Beijing, the People's Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. is a subsidiary of Beijing Pharmaceutical Group Co., Ltd.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥10.95 B |
| EBITDA | CN¥2.01 B |
| Gross Profit TTM | CN¥6.29 B |
| Profit Margin | 14.44% |
| Operating Margin | 15.81% |
| Quarterly Revenue Growth | -3.00% |
China Resources Double-Crane Pharmaceutical Co.,Ltd. has the following listings and related stock indices.
Stock: SSE: 600062 wb_incandescent